Primary Adenoid Cystic Carcinoma of the Peripheral Lungs

Shinohara, Shinji; Hanagiri, Takeshi; Takenaka, Masaru; Oka, Soichi; Chikaishi, Yasuhiro; Shimokawa, Hidehiko; Nakagawa, Makoto; Uramoto, Hidetaka; Saito, Tomoko; Tanaka, Fumihiro

doi:10.7888/juoeh.37.121

Cited by 6 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tracheal ACC is a rare low‐grade malignant neoplasm and primarily occurs in the trachea and bronchi, originating from ducts in the mucous glands. Tracheal ACC accounts for 0.04–0.2% of lung cancer cases and is distributed equally between genders . The age of onset ranges from 40 to 59 years; our patient was 59.…”

Section: Discussionmentioning

confidence: 79%

Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma

Wang

2017

Thoracic Cancer

View full text Add to dashboard Cite

A 57‐year‐old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantly relieved. Treatment with apatinib mesylate represents a novel method of treatment for tracheal adenoid cystic carcinoma.

show abstract

Section: Discussionmentioning

confidence: 79%

Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma

Wang

2017

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Peripheral lung ACC may arise from subsegmental bronchi, where the glandular distribution is more sparse. The incidence of ACC from the peripheral lung is relatively low and may be closely related to the distribution of glandular cells 7,8 . Although TACC and LACC have similar histological features, they differ in incidence, clinical features, prognosis, and treatment, and should be treated differently.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of ACC from the peripheral lung is relatively low and may be closely related to the distribution of glandular cells. 7 , 8 Although TACC and LACC have similar histological features, they differ in incidence, clinical features, prognosis, and treatment, and should be treated differently. To the best of our knowledge, this is the first study to systematically and comprehensively compare different tumor location and its relationship with clinical features, treatment modality, and prognosis for patients with thoracic ACC.…”

Section: Discussionmentioning

confidence: 99%

A population study comparing tracheal and lung adenoid cystic carcinoma

Gu,

Lai,

Wang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThoracic adenoid cystic carcinoma (ACC) is rare, and the differences between tracheal and lung lesions have not been fully understood.MethodsPatients were identified from a Chinese cancer center (FUSCC) (2005–2022) and the Surveillance, Epidemiology, and End Results (SEER) database (2000–2019). Incidence was calculated and trends were quantified. Clinicopathological features and overall survival (OS) were analyzed. Nomograms predicting OS were constructed.ResultsTotally, 55 tracheal adenoid cystic carcinoma (TACC) and 25 lung and bronchus adenoid cystic carcinoma (LACC) were included in a Chinese cohort, 121 TACC and 162 LACC included in the SEER cohort. There were larger tumor sizes, more lymph nodes and distant metastases for LACC than TACC patients. TACC patients are more likely to get local treatments. Patients with LACC had significantly worse median OS than patients with TACC (SEER cohort: 68.0 months vs. 109.0 months, p = 0.001, Chinese cohort: 62.9 months vs. 124.8 months, p = 0.061). Age, lymph node metastasis, distant metastasis and local treatment were identified as independent prognostic factors for OS of TACC. Distant metastasis and local treatment were identified for LACC. Specifically, surgery alone or in combination with radiotherapy is crucial for improving survival in both TACC and LACC. Only TACC benefits from radiotherapy alone, while chemotherapy does not improve survival for either. The nomograms constructed using these factors revealed good prognostic accuracy.ConclusionsLACC is more aggressive and has a worse prognosis than TACC. TACC patients have more opportunities for local treatment, which is important for the prognosis of both TACC and LACC. Nomograms were created for TACC and LACC to aid in personalized survival predictions and clinical decisions.

show abstract

“…However, its presence in the pulmonary system is uncommon. Most tumors occur in the trachea and mainstem bronchi, but peripheral tumors from glands of small bronchi have occasionally been reported[ 6 - 8 ]. Women are more often affected than men, and the peak age of incidence occurs between the 4th and 5th decades of life, which is earlier than lung cancer[ 9 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

Rapid response to radiotherapy in unresectable tracheal adenoid cystic carcinoma: A case report

Wu¹,

Xu²

2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Adenoid cystic carcinoma (ACC) occurs mainly in the head and neck. Tracheal ACC (TACC) is uncommon. Primary resection is recommended as the main treatment of choice, and radiotherapy is considered for residual disease in the postoperative setting. Definitive radiotherapy is an alternative approach to cure unresectable TACC. As the status of radiosensitivity in TACC is uncertain, the evidence for radiotherapy in unresectable TACC is not well established, especially in terms of the optimal dosage and its response evaluation. Herein, we report a case of locally advanced TACC. CASE SUMMARY A 49-year-old woman was diagnosed with TACC, which included a range of lesions arising in the upper trachea extending caudally 2 cm to 7 cm of the glottis. She was treated with definitive radiotherapy, given the low likelihood of complete resection of the disease. Due to the indolent growth and the propensity for infiltration along the airways, the scheduled radiation dose of 76 Gy in 38 fractions with 6-MV X-ray delivered by intensity-modulated radiotherapy was conducted to the primary tumor volume. After irradiation of 40 Gy, the patient’s dyspnea on exertion was dramatically relieved and bronchoscopy revealed that the previous large polypoid intra-luminal mass was significantly eliminated, with near-complete response. The patient completed two phases of scheduled radiotherapy, and acute reactions to treatment included subjective chest tightness and grade 2 esophagitis, managed medically. After 5 years of treatment, the patient is alive without recurrent disease, and there were no serious late radiation esophagus and lung damage, with only slight dysphagia without perforation and fistula. CONCLUSION Taken together, TACC is uncommon and the treatment of unresectable TACC is challenging. This case indicated that patients with unresectable TACC who rapidly respond to radiation may benefit from primary radical radiotherapy. Radiotherapy may be considered an effective alternative treatment modality.

show abstract

Primary Adenoid Cystic Carcinoma of the Peripheral Lungs

Cited by 6 publications

References 21 publications

Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma

Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma

A population study comparing tracheal and lung adenoid cystic carcinoma

Rapid response to radiotherapy in unresectable tracheal adenoid cystic carcinoma: A case report

Contact Info

Product

Resources

About